Alkermes plc
For the period ended Dec 31, 2024. Filed Feb 12, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 12, 2025
ALKS$46.47+0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
(a)(1) Consolidated Financial Statements—The consolidated financial statements of Alkermes plc, as required by this item, are submitted in a separate section beginning on page F-1 of this Annual Report, as follows:
| Financial Statement | Page Number |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 238) | F-1 |
| Consolidated Balance Sheets | F-3 |
| Consolidated Statements of Operations and Comprehensive Income (Loss) | F-4 |
| Consolidated Statements of Shareholders’ Equity | F-5 |
| Consolidated Statements of Cash Flows | F-6 |
| Notes to the Consolidated Financial Statements | F-7 |
(2) Financial Statement Schedules—All schedules have been omitted because the absence of conditions under which they are required or because the required information is included in the consolidated financial statements or notes thereto.
(3) The exhibits listed in the below Exhibit Index are filed or furnished as part of this Annual Report or are incorporated into this Annual Report by reference.
EXHIBIT INDEX
| Incorporated by reference herein | |||
| Exhibit No. | Description of Exhibit | Form | Date |
| 2.2 ** § | Agreement and Plan of Merger, dated November 14, 2019 by and among Alkermes, Inc., Thinker Merger Sub, Inc., Alkermes plc, Rodin Therapeutics, Inc., and Shareholder Representative Services LLC, as Company Equityholder Representative. | Exhibit 2.1 to the Alkermes plc Current Report on Form 8-K (File No. 001-35299) | November 25, 2019 |
| 2.3 § | Separation Agreement, dated as of November 13, 2023, by and between Alkermes plc and Mural Oncology plc. | Exhibit 2.1 to the Alkermes plc Current Report on Form 8-K (File No. 001-35299) | November 15, 2023 |
| 3.1 | Memorandum and Articles of Association of Alkermes plc. | Exhibit 3.1 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) | May 1, 2024 |
| 4.1 # | Description of Securities. | ||
| 10.1 | Lease between Alkermes, Inc. and PDM Unit 850, LLC, dated as of April 22, 2009. | Exhibit 10.5 to the Alkermes, Inc. Annual Report on Form 10-K (File No. 001-14131) | May 28, 2009 |
| 10.1A | First Amendment to Lease between Alkermes, Inc. and PDM Unit 850, LLC, dated as of June 18, 2009. | Exhibit 10.2 to the Alkermes, Inc. Quarterly Report on Form 10-Q (File No. 001-14131) | August 6, 2009 |
| 10.1B | Second Amendment to Lease between Alkermes, Inc. and PDM Unit 850, LLC, dated as of November 12, 2013. | Exhibit 10.74 to the Alkermes plc Transition Report on Form 10-KT (File No. 001-35299) | February 27, 2014 |
| 10.1C | Third Amendment to Lease between Alkermes, Inc. and PDM 850 Unit, LLC, dated as of May 15, 2014. | Exhibit 10.2 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) | July 31, 2014 |
| 10.1D | Fourth Amendment to Lease between Alkermes, Inc. and GI TC 850 Winter Street, LLC, dated as of December 30, 2014. | Exhibit 10.7 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) | July 30, 2015 |
| 10.1E | Fifth Amendment to Lease between Alkermes, Inc. and GI TC 850 Winter Street, LLC, dated as of October 31, 2018. | Exhibit 10.1.5 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) | February 15, 2019 |
| 10.1F | Sixth Amendment to Lease between Alkermes, Inc. and GI TC 850 Winter Street, LLC, dated as of July 24, 2020. | Exhibit 10.1 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) | October 29, 2020 |
| Incorporated by reference herein | |||
| Exhibit No. | Description of Exhibit | Form | Date |
| 10.2 | License Agreement, dated as of February 13, 1996, between Medisorb Technologies International L.P. and Janssen Pharmaceutica Inc. (United States) (assigned to Alkermes, Inc. in July 2006). | Exhibit 10.2 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) | February 25, 2016 |
| 10.2A * | Third Amendment to Development Agreement, Second Amendment to Manufacturing and Supply Agreement and First Amendment to License Agreements by and between Janssen Pharmaceutica International, Janssen Pharmaceutica Inc. and Alkermes Controlled Therapeutics Inc. II, dated April 1, 2000 (assigned to Alkermes, Inc. in July 2006). | Exhibit 10.5 to the Alkermes, Inc. Quarterly Report on Form 10-Q (File No. 001-14131) | February 8, 2005 |
| 10.2B * | Second Amendment, dated as of August 16, 2012, to the License Agreement, dated as of February 13, 1996, as amended, by and between Alkermes, Inc. and Janssen Pharmaceutica Inc. and the License Agreement, dated as of February 21, 1996, as amended, by and between Alkermes, Inc. and JPI Pharmaceutica International, and the Fifth Amendment, dated as of August 16, 2012, to the Manufacturing and Supply Agreement, dated as of August 6, 1997, as amended, by and between Alkermes, Inc., Janssen Pharmaceutica Inc. and JPI Pharmaceutica International. | Exhibit 10.3 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) | November 1, 2012 |
| 10.3 | License Agreement, dated as of February 21, 1996, between Medisorb Technologies International L.P. and Janssen Pharmaceutica International (worldwide except United States) (assigned to Alkermes, Inc. in July 2006). | Exhibit 10.3 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) | February 25, 2016 |
| 10.4 | Manufacturing and Supply Agreement, dated August 6, 1997, by and among JPI Pharmaceutica International, Janssen Pharmaceutica, Inc. and Alkermes Controlled Therapeutics Inc. II (assigned to Alkermes, Inc. in July 2006). | Exhibit 10.4 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) | February 25, 2016 |
| 10.4A * | Fourth Amendment to Development Agreement and First Amendment to Manufacturing and Supply Agreement by and between Janssen Pharmaceutica International, Janssen Pharmaceutica Products, L.P. and Alkermes Controlled Therapeutics Inc. II, dated December 20, 2000 (assigned to Alkermes, Inc. in July 2006). | Exhibit 10.4 to the Alkermes, Inc. Quarterly Report on Form 10-Q (File No. 001-14131) | February 8, 2005 |
| 10.4B | Addendum to the Manufacturing and Supply Agreement by and among JPI Pharmaceutica International, Janssen Pharmaceutica Inc. and Alkermes Controlled Therapeutics Inc. II, dated August 1, 2001. | Exhibit 10.4.2 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) | February 25, 2016 |
| 10.4C | Letter Agreement and Exhibits to Manufacturing and Supply Agreement, dated February 1, 2002, by and among JPI Pharmaceutica International, Janssen Pharmaceutica Inc. and Alkermes Controlled Therapeutics Inc. II (assigned to Alkermes, Inc. in July 2006). | Exhibit 10.4.3 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) | February 25, 2016 |
| 10.4D * | Amendment to Manufacturing and Supply Agreement by and between JPI Pharmaceutica International, Janssen Pharmaceutica Inc. and Alkermes Controlled Therapeutics Inc. II, dated December 22, 2003 (assigned to Alkermes, Inc. in July 2006). | Exhibit 10.6 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 011-35299) | July 30, 2015 |
| 10.4E * | Fourth Amendment to Manufacturing and Supply Agreement by and between JPI Pharmaceutica International, Janssen Pharmaceutica Inc. and Alkermes Controlled Therapeutics Inc. II, dated January 10, 2005 (assigned to Alkermes, Inc. in July 2006). | Exhibit 10.9 to the Alkermes, Inc. Quarterly Report on Form 10-Q (File No. 001-14131) | February 8, 2005 |
| 10.4F * | Sixth Amendment to Manufacturing and Supply Agreement by and between JPI Pharmaceutica International, Janssen Pharmaceutica Inc. and Alkermes Controlled Therapeutics Inc. II (assigned to Alkermes, Inc. in July 2006), effective as of July 1, 2018. | Exhibit 10.11 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 011-35299) | October 23, 2018 |
| Incorporated by reference herein | |||
| Exhibit No. | Description of Exhibit | Form | Date |
| 10.5 * | Agreement by and between JPI Pharmaceutica International, Janssen Pharmaceutica Inc. and Alkermes Controlled Therapeutics Inc. II, dated December 21, 2002 (assigned to Alkermes, Inc. in July 2006). | Exhibit 10.6 to the Alkermes, Inc. Quarterly Report on Form 10-Q (File No. 001-14131) | February 8, 2005 |
| 10.5A * | Amendment to Agreement by and between JPI Pharmaceutica International, Janssen Pharmaceutica Inc. and Alkermes Controlled Therapeutics Inc. II, dated December 16, 2003 (assigned to Alkermes, Inc. in July 2006). | Exhibit 10.7 to the Alkermes, Inc. Quarterly Report on Form 10-Q (File No. 001-14131) | February 8, 2005 |
| 10.6 ** | License Agreement by and among Elan Pharmaceutical Research Corp., d/b/a Nanosystems and Elan Pharma International Limited and Janssen Pharmaceutica N.V. dated as of March 31, 1999. | Exhibit 10.1 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) | April 26, 2023 |
| 10.6A | First Amendment, dated as of July 31, 2003, to the License Agreement by and among Elan Drug Delivery, Inc. (formerly Elan Pharmaceutical Research Corp.) and Elan Pharma International Limited and Janssen Pharmaceutica NV dated March 31, 1999. | Exhibit 10.24 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) | May 23, 2013 |
| 10.6B ** | Agreement Amendment No. 2, dated as of July 31, 2009, to the License Agreement by and among Elan Pharmaceutical Research Corp., d/b/a Nanosystems and Elan Pharma International Limited and Janssen Pharmaceutica N.V. dated as of March 31, 1999, as amended by the First Amendment, dated as of July 31, 2003. | Exhibit 10.2 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) | April 26, 2023 |
| 10.7 * | License and Collaboration Agreement, dated November 27, 2017, by and between Alkermes Pharma Ireland Limited and Biogen International GmbH (as successor to Biogen Swiss Manufacturing GmbH). | Exhibit 10.10 to the Alkermes plc Annual Report on Form 10-K (File No. 011-35299) | February 16, 2018 |
| 10.7A * | First Amendment to License and Collaboration Agreement between Alkermes Pharma Ireland Limited and Biogen International GmbH (as successor to Biogen Swiss Manufacturing GmbH), effective as of October 3, 2018. | Exhibit 10.12 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 011-35299) | October 23, 2018 |
| 10.7B | Second Amendment to License and Collaboration Agreement between Alkermes Pharma Ireland Limited and Biogen International GmbH (as successor to Biogen Swiss Manufacturing GmbH), effective as of January 31, 2019. | Exhibit 10.1 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 011-35299) | April 25, 2019 |
| 10.7C ** | Third Amendment to License and Collaboration Agreement between Alkermes Pharma Ireland Limited and Biogen International GmbH (as successor to Biogen Swiss Manufacturing GmbH), effective as of October 30, 2019. | Exhibit 10.10.3 to the Alkermes plc Annual Report on Form 10-K (File No. 011-35299) | February 13, 2020 |
| 10.7D ** | Fourth Amendment to License and Collaboration Agreement between Alkermes Pharma Ireland Limited and Biogen International GmbH (as successor to Biogen Swiss Manufacturing GmbH), effective as of August 25, 2022. | Exhibit 10.1 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 011-35299) | November 2, 2022 |
| 10.7E ** | Fifth Amendment to License and Collaboration Agreement between Alkermes Pharma Ireland Limited and Biogen International GmbH (as successor to Biogen Swiss Manufacturing GmbH), effective as of June 7, 2024. | Exhibit 10.1 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 011-35299) | July 24, 2024 |
| 10.8 | Lease, dated March 23, 2018, by and between Alkermes, Inc. and PDM 900 Unit, LLC. | Exhibit 10.4 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 011-35299) | April 26, 2018 |
| 10.8A | First Amendment to Lease, dated June 21, 2018, by and between Alkermes, Inc. and PDM 900 Unit, LLC. | Exhibit 10.2 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) | July 26, 2018 |
| 10.8B | Second Amendment to Lease, dated May 10, 2019, by and between Alkermes, Inc. and PDM 900 Unit, LLC. | Exhibit 10.2 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) | July 25, 2019 |
| Incorporated by reference herein | |||
| Exhibit No. | Description of Exhibit | Form | Date |
|---|---|---|---|
| 10.9 ** | Confidential Settlement and License Agreement, dated August 29, 2023, by and among Alkermes, Inc., Alkermes Pharma Ireland Limited and Teva Pharmaceuticals USA, Inc. | Exhibit 10.1 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) | October 25, 2023 |
| 10.10 § | Tax Matters Agreement, dated November 13, 2023, by and between Alkermes plc and Mural Oncology plc. | Exhibit 10.1 to the Alkermes plc Current Report on Form 8-K (File No. 001-35299) | November 15, 2023 |
| 10.11 ** § | Asset Purchase Agreement, dated December 13, 2023, by and between Alkermes Pharma Ireland Limited, Novo Nordisk Production Ireland Limited and Novo Nordisk A/S. | Exhibit 10.16 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) | February 21, 2024 |
| 10.12 † | Employment Agreement, dated as of December 12, 2007, by and between Richard F. Pops and Alkermes, Inc. | Exhibit 10.1 to the Alkermes, Inc. Quarterly Report on Form 10-Q (File No. 001-14131) | February 11, 2008 |
| 10.12A † | Amendment to Employment Agreement, dated as of October 7, 2008, by and between Alkermes, Inc. and Richard F. Pops. | Exhibit 10.5 to the Alkermes, Inc. Current Report on Form 8-K (File No. 001-14131) | October 7, 2008 |
| 10.12B † | Amendment No. 2 to Employment Agreement, dated as of September 10, 2009 by and between Richard F. Pops and Alkermes, Inc. | Exhibit 10.2 to the Alkermes, Inc. Current Report on Form 8-K (File No. 001-14131) | September 11, 2009 |
| 10.13 † | Form of Employment Agreement, as amended by the Form of Amendment to Employment Agreement set forth in 10.12.1, entered into by and between Alkermes, Inc. and Blair C. Jackson. | Exhibit 10.3 to the Alkermes, Inc. Quarterly Report on Form 10-Q (File No. 001-14131) | February 11, 2008 |
| 10.13A † | Form of Amendment to Employment Agreement with Alkermes, Inc. | Exhibit 10.7 to the Alkermes, Inc. Current Report on Form 8-K (File No. 001-14131) | October 7, 2008 |
| 10.14 † | Form of Employment Agreement entered into by and between Alkermes, Inc. and each of Iain M. Brown, David J. Gaffin, Craig C. Hopkinson, M.D. and Christian Todd Nichols. | Exhibit 10.1 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 011-35299) | November 2, 2016 |
| 10.14A† | Offer Letter by and between Alkermes, Inc. and Craig C. Hopkinson M.D., effective as of April 24, 2017. | Exhibit 10.17.1 to the Alkermes plc Annual Report on Form 10-K (File No. 011-35299) | February 16, 2018 |
| 10.14B † | Offer Letter, dated March 29, 2019, by and between Alkermes, Inc. and Christian Todd Nichols. | Exhibit 10.1 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 011-35299) | July 29, 2020 |
| 10.15 † | Form of Indemnification Agreement entered into by and between Alkermes, Inc. and each of the Directors and Secretaries of Alkermes plc and its Irish subsidiaries. | Exhibit 10.2 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) | April 29, 2020 |
| 10.16 † | Form of Deed of Indemnification entered into by and between each of the Directors, Secretaries and executive officers of Alkermes plc and its subsidiaries. | Exhibit 10.1 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) | April 29, 2020 |
| 10.17† | Alkermes plc Amended and Restated 2008 Stock Option and Incentive Plan, as amended. | Exhibit 10.1 to the Alkermes plc Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 (File No. 001-35299) | April 27, 2017 |
| 10.17A † | Form of Stock Option Award Certificate (Non-Employee Director) under the Alkermes plc Amended and Restated 2008 Stock Option and Incentive Plan, as amended. | Exhibit 10.4 to the Alkermes plc Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 (File No. 001-35299) | April 28, 2016 |
| 10.17B † | Form of Restricted Stock Unit Award Certificate (Time Vesting Only – Irish) under the Alkermes plc Amended and Restated 2008 Stock Option and Incentive Plan, as amended. | Exhibit 10.5 to the Alkermes plc Quarterly Report on Form 10-Q for the quarter ended | April 28, 2016 |
| Incorporated by reference herein | |||
| Exhibit No. | Description of Exhibit | Form | Date |
|---|---|---|---|
| March 31, 2016 (File No. 001-35299) | |||
| 10.17C † | Form of Restricted Stock Unit Award Certificate (Time Vesting Only – U.S.) under the Alkermes plc Amended and Restated 2008 Stock Option and Incentive Plan, as amended. | Exhibit 10.6 to the Alkermes plc Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 (File No. 001-35299) | April 28, 2016 |
| 10.17D † | Form of Stock Option Award Certificate (Time Vesting Non-Qualified Option – Irish) under the Alkermes plc Amended and Restated 2008 Stock Option and Incentive Plan, as amended. | Exhibit 10.7 to the Alkermes plc Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 (File No. 001-35299) | April 28, 2016 |
| 10.17E † | Form Stock Option Award Certificate (Time Vesting Non-Qualified Option – U.S.) under the Alkermes plc Amended and Restated 2008 Stock Option and Incentive Plan, as amended. | Exhibit 10.8 to the Alkermes plc Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 (File No. 001-35299) | April 28, 2016 |
| 10.17F † | Form of Stock Option Award Certificate (Incentive Stock Option – U.S.) under the Alkermes plc Amended and Restated 2008 Stock Option and Incentive Plan, as amended. | Exhibit 10.9 to the Alkermes plc Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 (File No. 001-35299) | April 28, 2016 |
| 10.17G † | Form of 2008 Restricted Stock Unit Award Certificate (Performance Vesting Only) under the Alkermes plc Amended and Restated 2008 Stock Option and Incentive Plan, as amended. | Exhibit 10.2 to the Alkermes, Inc. Current Report on Form 8-K (File No. 001-14131) | May 22, 2009 |
| 10.18† | Alkermes plc 2011 Stock Option and Incentive Plan, as amended. | Exhibit 10.1 to the Alkermes plc Current Report on Form 8-K (File No. 011-35299) | May 24, 2017 |
| 10.18A † | Form of Incentive Stock Option Award Certificate under the Alkermes plc 2011 Stock Option and Incentive Plan, as amended. | Exhibit 10.1 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) | October 23, 2018 |
| 10.18B † | Form of Non-Qualified Stock Option (Employee) Award Certificate under the Alkermes plc 2011 Stock Option and Incentive Plan, as amended. | Exhibit 10.2 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) | October 23, 2018 |
| 10.18C † | Form of Restricted Stock Unit (Time-Vesting) Award Certificate under the Alkermes plc 2011 Stock Option and Incentive Plan, as amended. | Exhibit 10.3 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) | October 23, 2018 |
| 10.18D † | Form of Restricted Stock Unit (Performance-Vesting) Award Certificate under the Alkermes plc 2011 Stock Option and Incentive Plan, as amended. | Exhibit 10.4 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) | October 23, 2018 |
| 10.18E † | Form of Non-Qualified Stock Option (Non-Employee Director) Award Certificate under the Alkermes plc 2011 Stock Option and Incentive Plan, as amended. | Exhibit 10.5 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) | October 23, 2018 |
| 10.19 † | Alkermes plc 2018 Stock Option and Incentive Plan, as amended. | Exhibit 10.1 to the Alkermes plc Current Report on Form 8-K (File No. 001-35299) | May 31, 2024 |
| 10.19A † | Form of Incentive Stock Option Award Certificate under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. | Exhibit 10.6 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) | October 23, 2018 |
| 10.19B † | Form of Non-Qualified Stock Option (Employee) Award Certificate under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. | Exhibit 10.7 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) | October 23, 2018 |
| 10.19C † | Form of Restricted Stock Unit (Time-Vesting) Award Certificate under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. | Exhibit 10.8 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) | October 23, 2018 |
| Incorporated by reference herein | |||
| Exhibit No. | Description of Exhibit | Form | Date |
| 10.19D † | Form of Restricted Stock Unit (Performance-Vesting) Award Certificate under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. | Exhibit 10.6 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) | July 29, 2020 |
| 10.19E † | Form of Non-Qualified Stock Option (Non-Employee Director) Award Certificate under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. | Exhibit 10.4 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) | July 29, 2020 |
| 10.19F † | Form of Non-Employee Director Restricted Stock Unit (Time-Vesting) Award Certificate under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. | Exhibit 10.5 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) | July 29, 2020 |
| 10.19G † | Form of Non-Employee Director New Director Grant Non-Qualified Stock Option Award Certificate under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. | Exhibit 10.1.1 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) | July 27, 2022 |
| 10.19H † | Form of Non-Employee Director New Director Grant Restricted Stock Unit (Time-Vesting) Award Certificate under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. | Exhibit 10.1.2 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) | July 27, 2022 |
| 10.19I † | Form of Incentive Stock Option Award Certificate for Reporting Officers under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. | Exhibit 10.19-9 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) | February 16, 2023 |
| 10.19J † | Form of Non-Qualified Stock Option Award Certificate for Reporting Officers under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. | Exhibit 10.19-10 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) | February 16, 2023 |
| 10.19K † | Form of Restricted Stock Unit (Time-Vesting) Award Certificate for Reporting Officers under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. | Exhibit 10.19-11 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) | February 16, 2023 |
| 10.19L † | Form of Restricted Stock Unit (Performance-Vesting) Award Certificate for Reporting Officers under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. | Exhibit 10.19-12 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) | February 16, 2023 |
| 10.19M † | Form of Restricted Stock Unit (Performance-Vesting) Award Certificate (rev. 2024) for Reporting Officers under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. | Exhibit 10.25M to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) | February 21, 2024 |
| 10.19N † | Form of Restricted Stock Unit (Performance-Vesting) Award Certificate (rev. 2024) under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. | Exhibit 10.25N to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) | February 21, 2024 |
| 10.19O † | Form of Non-Employee Director Non-Qualified Stock Option Award Certificate (rev. 2024) under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. | Exhibit 10.2A to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) | July 24, 2024 |
| 10.19P † | Form of Non-Employee Director Restricted Stock Unit Award (Time-Vesting) Award Certificate (rev. 2024) under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. | Exhibit 10.2A to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) | July 24, 2024 |
| 19.1 # | Alkermes plc Insider Trading Policy. | ||
| 21.1 # | List of subsidiaries. | ||
| 23.1 # | Consent of PricewaterhouseCoopers LLP, an independent registered public accounting firm. | ||
| 24.1 # | Power of Attorney (included on the signature pages hereto). | ||
| 31.1 # | Certification Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934. | ||
| Incorporated by reference herein | |||
| Exhibit No. | Description of Exhibit | Form | Date |
| 31.2 # | Certification Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934. | ||
| 32.1 ‡ | Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||
| 97 † | Alkermes plc Incentive Compensation Recoupment Policy. | Exhibit 97 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) | February 21, 2024 |
| 101.SCH # | Inline XBRL Taxonomy Extension Schema with Embedded Linkbases Document. | ||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101). | ||
| † | Indicates a management contract or any compensatory plan, contract or arrangement. | ||
| # | Filed herewith. | ||
| ‡ | Furnished herewith. | ||
| * | Confidential treatment has been granted or requested for certain portions of this exhibit. Such portions have been filed separately with the SEC pursuant to a confidential treatment request. | ||
| ** | Portions of this exhibit (indicated by “[**]”) have been omitted pursuant to Item 601(b) of Regulation S-K. The Company undertakes to furnish an unredacted copy of this exhibit upon request by the U.S. Securities and Exchange Commission. | ||
| § | Schedules and similar attachments to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company undertakes to furnish copies of any omitted schedules and similar attachments upon request by the U.S. Securities and Exchange Commission. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.